Inventiva reports it
Inventiva reports its 2023 full-year results
March 27, 2024 16:00 ET | INVENTIVA
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit...
Inventiva publie ses
Inventiva publie ses résultats annuels 2023
March 27, 2024 16:00 ET | INVENTIVA
Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022Trésorerie et équivalents de trésorerie de 26,9 millions d’euros, dépôt à...
One Bio.jpg
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
March 27, 2024 08:00 ET | One Biosciences
PARIS, March 27, 2024 (GLOBE NEWSWIRE) -- One Biosciences, a Home Biosciences biotech company, leveraging the power of single-cell analysis and A.I. to identify a new generation of precision...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 25, 2024 06:15 ET | Sagimet Biosciences Inc.
Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis ...
Lightbridge Corporation Logo
Lightbridge Senior Executives Assume Key Positions in Prestigious Nuclear Energy Industry Groups
March 21, 2024 08:00 ET | Lightbridge Corporation
RESTON, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced the appointments of senior...
Unknown.jpg
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
March 19, 2024 06:00 ET | Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
March 18, 2024 11:30 ET | RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
Rezdiffra
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
March 14, 2024 16:15 ET | Madrigal Pharmaceuticals, Inc.
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved...
SCV Safety Summit
SmallCapVoice.com Inc. (“SCV”) to Host First Annual Safety Summit featuring Up-and-Coming Public Companies AUSTIN, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- Austin, Texas-based SmallCapVoice.com Inc. (“SCV”) announced an upcoming webinar and live Q&A session with several rising stars in key support...
logo.jpg
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
March 11, 2024 07:15 ET | Lexicon Pharmaceuticals, Inc.
Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase...